IL13 and COVID-19: However, both in vitro experiments examining IL-13 effects on SARS-CoV-2 infection and empirical data on COVID-19 outcomes among T2-high and T2-low patients will be needed to determine whether this common airway inflammatory endotype ultimately protects against, exacerbates, or has no effect on COVID-19 illness.